Key result
Longer-term use of ACE inhibitors (OR 1.0; 95% CI 0.7-1.5) or CCBs (OR 0.9; 95% CI 0.7-1.2) was not associated with an altered risk of developing breast cancer compared with nonusers.
Why the study?
Does previous exposure to ACE inhibitors, calcium channel blockers, or beta-blockers affect the risk of developing breast cancer in postmenopausal women?
Population
17,861 postmenopausal women from the General Practice Research Database
Comparison
Previous exposure to ACE inhibitors, calcium… vs Nonusers of antihypertensive drugs
Design
Case-control
Authors
Loading...
Observational data show no breast cancer link with ACE inhibitors or CCBs; leaves open need for prospective confirmation.
Case-Control (n=17,861)
Does previous exposure to ACE inhibitors, calcium channel blockers, or beta-blockers affect the risk of developing breast cancer in postmenopausal women?
Odds Ratio: 1 (95% CI 0.7–1.5)
Long-term use of common antihypertensive medications, including ACE inhibitors, calcium channel blockers, and beta-blockers, does not affect the risk of developing breast cancer in postmenopausal women.
Meier et al. (2000) conducted a case-control in Breast cancer (n=17,861). ACE inhibitors and calcium channel blockers vs. Nonusers of antihypertensive drugs was evaluated on Incident breast cancer (OR 1.0, 95% CI 0.7-1.5). Longer-term use of ACE inhibitors (OR 1.0; 95% CI 0.7-1.5) or CCBs (OR 0.9; 95% CI 0.7-1.2) was not associated with an altered risk of developing breast cancer compared with nonusers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: